TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02387801
Drug: Ixekizumab
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT02764723
Drug: Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
Study: NCT02764723
Drug: Isobaric ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
Study: NCT00167102
Drug: Alefacept
Normalized name: Alefacept
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
Study: NCT01219036
Drug: Budesonide (directly observed)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 1600 micrograms daily directly observed for 7 days
Study: NCT03789032
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vadadustat 300 mg
Study: NCT03789032
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Rabeprazole
Study: NCT00799045
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
Study: NCT00387374
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00387374
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00221624
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00221624
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00221624
Drug: amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01095653
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 5 mg, Once daily, 24 weeks
Study: NCT01095653
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10 mg, Once daily, 24 weeks
Study: NCT01095653
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Study: NCT01095653
Drug: Dapagliflozin Placebo
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks
Study: NCT00058149
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00058149
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03651518
Drug: Kineret
Normalized name: Kineret
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg, once/day sc 6 months
Study: NCT03651518
Drug: Humira
Normalized name: Humira
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg/15 days sc 6 months
Study: NCT03651518
Drug: Stelara
Normalized name: Stelara
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg/12 weeks sc, 6 months
Study: NCT03651518
Drug: Cosentyx
Normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg sc every week for 1 month, then 300 mg/month sc for 5 months
Study: NCT03651518
Drug: Roactemra
Normalized name: Actemra
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480 mg/perf/4 weeks 6 months
Study: NCT03651518
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 sessions of 1000 mg at inclusion and 15 days after inclusion
Study: NCT02069730
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE).
Study: NCT02069730
Drug: EGFR or HER2 Inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor
Study: NCT02069730
Drug: C-KIT Inhibitor
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor
Study: NCT02069730
Drug: MEK or PI3K Inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor
Study: NCT01564095
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
Study: NCT02024022
Drug: Individualized approach
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00594542
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
Study: NCT03009838
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets 2.5 mg
Study: NCT02430896
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
Study: NCT02430896
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
Study: NCT03190265
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
Study: NCT03190265
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
Study: NCT03190265
Drug: GVAX Pancreas Vaccine
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
Study: NCT03190265
Drug: CRS-207
Normalized name: CRS-207
DrugBank: CRS-207 (DB17323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
Study: NCT03311672
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
Study: NCT03190265
Drug: CRS-207
Normalized name: CRS-207
DrugBank: CRS-207 (DB17323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
Study: NCT02599649
Drug: Lirilumab
Normalized name: Lirilumab
DrugBank: Lirilumab (DB11754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg by vein every 4 weeks.
Study: NCT02599649
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
Study: NCT02599649
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m\^2 by vein for 7 days of a 28 day cycle.
Study: NCT00792025
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01180816
Drug: Super-Selective Intraarterial Intracranial Infusion of Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
Study: NCT00780637
Drug: Bradykinin
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
Study: NCT00747344
Drug: Ustekinumab 45 mg - CP
Normalized name: ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 45 mg, Weeks 0-12
Study: NCT00747344
Drug: Placebo to ustekinumab 45 mg - after CP
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
Study: NCT00747344
Drug: Ustekinumab 45 mg - after CP
Normalized name: ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
Study: NCT01329796
Drug: Lignocaine
Normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
Study: NCT01329796
Drug: Ringers Solution
Normalized name: ringers solution,acetated
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
Study: NCT00765882
Drug: Linaclotide 290 micrograms
Normalized name: linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study: NCT00765882
Drug: Linaclotide 145 micrograms
Normalized name: linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study: NCT03425708
Drug: 20mg Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants take 20mg febuxostat pill once a day for at least six months.
Study: NCT02337530
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02337530
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02337530
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02337530
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03351114
Drug: Crisaborole
Normalized name: Crisaborole
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apply Crisaborole 2% ointment to affected skin twice per day.
Study: NCT03425708
Drug: 40mg Febuxostat
Normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants take 40mg febuxostat pill once a day for at least six months.
Study: NCT03362099
Drug: Varenicline Tartrate or bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
Study: NCT04359290
Drug: Ruxolitinib administration
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
Study: NCT00272948
Drug: Defibrotide
Normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide 25 mg/kg/d
Study: NCT00272948
Drug: Defibrotide
Normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
Study: NCT00272948
Drug: Defibrotide
Normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
Study: NCT01665430
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
Study: NCT02125357
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
Study: NCT02125357
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160mg PO OD as per standard of care.
Study: NCT01430507
Drug: Revamilast
Normalized name: Revamilast
DrugBank: Revamilast (DB11838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Low dose, Once daily for 12 weeks
Study: NCT01430507
Drug: Revamilast
Normalized name: Revamilast
DrugBank: Revamilast (DB11838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Medium dose, Once daily for 12 weeks
Study: NCT01430507
Drug: Revamilast
Normalized name: Revamilast
DrugBank: Revamilast (DB11838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, High dose, Once daily for 12 weeks
Study: NCT01523548
Drug: Carbon Monoxide
Normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
Study: NCT00180024
Drug: irbesartan (drug)
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261129
Drug: Telmisartan film-coated tablet
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02261129
Drug: Telmisartan uncoated tablet
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00292838
Drug: fluticasone 25, 50, 100, 200 mcg
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02943356
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with Tadalafil for 8 weeks
Study: NCT01669421
Drug: Alpha-1 Antitrypsin (human)
Normalized name: alpha 1-antitrypsin
DrugBank: Trypsin (DB11237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Study: NCT01605227
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets taken orally once-daily
Study: NCT01605227
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
Study: NCT04380103
Drug: XELOXIRI/Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
Study: NCT03745352
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT03745352
Drug: Pevonedistat
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00536874
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
Study: NCT00536874
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
Study: NCT03920267
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT00084019
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00084019
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02649855
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is commercially available. It will be administered at 75 mg/m(2) intravenously.
Study: NCT01476280
Drug: palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.075mg immediately before induction of anesthesia
Study: NCT01476280
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 0.3mg immediately before induction of anesthesia
Study: NCT03638869
Drug: REL-1017
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
Study: NCT02818036
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00042432
Drug: cinacalcet (AMG 073)
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
Study: NCT03209232
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
Study: NCT00869050
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle.
Study: NCT00610441
Drug: MK-8777
Normalized name: MK-8777
DrugBank: MK-8777 (DB18904)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03950687
Drug: Recombinant Human Erythropoiesis Injection (CHO cell)
Normalized name: hyaluronidase, human recombinant Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study: NCT03950687
Drug: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
Normalized name: Granulocyte colony stimulating factor 3 (CHO cell derived)
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Study: NCT02966795
Drug: Glecaprevir/Pibrentasvir
Normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-dose combination tablets taken orally once a day.